Lead generation: Reality check on commonly held views

Expert Opinion on Drug Discovery

Volumn 3, Issue 7, 2008, Pages 733-744

  Fotouhi, Nader ^a   Gillespie, Paul ^a   Goodnow Jr , Robert ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Drug discovery; High throughput chemistry; Lipinski rules; Natural products; Peptides

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ACECLIDINE; ARTEMISIN; ATORVASTATIN; CALCITRIOL; CERIVASTATIN; COMPACTIN; DIGOXIN; ENFUVIRTIDE; EXENDIN 4; FLUINDOSTATIN; IMATINIB; IMIDAZOLINE; LEUPRORELIN; MEVINOLIN; NATURAL PRODUCT; NEW DRUG; NLN 0675; NLN 0685; PHOSPHOTRANSFERASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; PRIMAQUINE; PROTIRELIN; R 411; ROSUVASTATIN; SIMVASTATIN; SORAFENIB; TOLNAFTATE; UNINDEXED DRUG;

COMBINATORIAL CHEMISTRY; COMBINATORIAL LIBRARY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG ISOLATION; DRUG LEGISLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR WEIGHT; NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 48049090902     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.7.733     Document Type: Review

References (74)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-26
2. According to SciFinder there are >1660 papers which reference Lipinski's 1997 paper (Ref 1)
3. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90
4. Benet LZ, Øie S, Schwatrz JB. Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors, Goodman & Gilman's The pharmacological basis of therapeutics ninth edition. New York. McGraw-Hill; 1995. p. 1736
5. Lamb E. Top 200 prescription drugs of 2006. Pharmacy Times 2007;73(5):34-7
6. Orange Book Information Data Files. FDA Website. U.S. Food and Drug Administration. Washington DC. Available from: www.fda.gov/cder/orange/ obreadme.htm [Last accessed: 2/4/2008]
7. Drews J. Genomic sciences and the medicine of tomorrow. Nat Biotech 1996;14:1516-8
8. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30
9. Fry DC. Protein-protein interactions as targets for small molecule drug discovery. Biopolymers 2006;84:535-52
10. Wells JL, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-9
11. Horspool KR, Lipinski CA. Advancing new drug delivery concepts to gain the lead. Drug Deliv Technol 2003;3:34-46
12. Tilley JW. Discovery and development of the VLA4 antagonist R411 for the treatment of asthma. Abstracts of Papers, 234th ACS National Meeting; 2007 August 19-23; Boston, MA, United States; MEDI-250
13. Hijazi Y, Welker H, Dorr AE, et al. Pharmacokinetics, safety, and tolerability of R411, a dual α4β1-α4β7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J Clin Pharm 2004;44:1368-78
14. Black JW, Kalindjian SB. Gastrin agonists and antagonists. Pharmacol Toxicol 2002;91:275-81
15. Afshar M. From genes to products: innovations in drug discovery. Drug Discov Today 2003;8:392-4
16. Black J. Future perspectives in pharmaceutical research. Pharm Policy Law 1999;1:85-92
17. Dolle RE, Le Bourdonnec B, Goodman AJ, et al. Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2006. J Comb Chem 2007;9:855-902
18. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44
19. Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000;287:1964-9
20. Barthel-Rosa LP, Gladysz JA. Chemistry in fluorous media: a user's guide to practical considerations in the application of fluorous catalysts and reagents. Coordin Chem Rev 1999;190-192:587-605
21. Ortholand J-Y, Ganesan A. Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol 2004;8:271-80
22. Kuntz KW, Snapper MW, Hoveyda AH. Combinatorial catalyst discovery. Curr Opin Chem Biol 1999;3:313-9
23. Zeng L, Burton L, Yung K, et al. Automated analytical/preparative high-performance liquid chromatography-mass spectrometry system for the rapid characterization and purification of compound libraries. J Chromatogr A 2002;794:3-13
24. Feher M, Schmidt JM. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003;43:218-27
25. Grabowski K, Schneider G. Properties and architecture of drugs and natural products revisited. Curr Chem Biol 2007;1:115-27
26. Shelat AA, Guy RK. The interdependence between screening methods and screening libraries. Curr Opin Chem Biol 2007;11:244-51
27. Martinez A, Kolvek SJ, Yip CLT, et al. Genetically modified bacterial strains and novel bacterial artificial chromosome shuttle vectors for constructing environmental libraries and detecting heterologous natural products in multiple expression hosts. Appl Environ Microbiol 2004;70:2452-63
28. Dobson CM. Chemical space and biology. Nature 2004;432:824-8
29. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000;17:215-34
30. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-37
31. Cragg GM, Newman DJ. Biodiversity: a continuing source of novel drug leads. Pure Appl Chem 2005;77:7-24
32. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77
33. Zhang J, McCombie G, Guenat C, Knochenmuss R. FT-ICR mass spectrometry in the drug discovery process. Drug Discov Today 2005;10:635-42
34. Chin Y-W, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. AAPS J 2006;8:E239-53
35. Stepp JR. The role of weeds as sources of pharmaceuticals. J Ethnopharmacol 2004;92:163-6
36. Vuorela P, Leinonen M, Saikku P, et al. Natural products in the process of finding new drug candidates. Curr Med Chem 2004;11:1375-89
37. Clardy J, Walsh C. Lessons from natural molecules. Nature 2004;432:829-37
38. Proudfoot JR. Drugs, leads and drug-likeness: an analysis of some recently launched drugs. Bioorg Med Chem Lett 2002;12:1647-50
39. Romano JH. Double-blind cross-over comparison of aceclidine and pilocarpine in open-angle glaucoma. Br J Ophthalmol 1970;54:510-21
40. Klayman DL. Qinghaosu (Aretemisinin): an antimalarial drug from China. Science 1985;228:1049-55
41. Anon. New drugs. Notice of approval of applications. Fed Regist 1966;31:9812
42. Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007;297:2251-63
43. Atmaca H, Tanriverdi F, Gokce C, et al. Do we still need the TRH stimulation test? Thyroid 2007;17:529-33
44. Christ-Crain M, Meier C, Roth C-B, et al. Basal TSH levels compared with TRH-stimulated TSH levels to diagnose different degrees of TSH suppression: diagnostic and therapeutic impact of assay performance. Eur J Clin Invest 2002;32:931-7
45. Schmitt CP, Ardissino G, Testa S, et al. Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 2003;18:440-4
46. Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 2001;41:856-64
47. Sneader W. Drug prototypes and their exploitation. John Wiley and Sons Ltd., Chichester; 1996
48. Oprea TI, Davis AM, Teague SJ, Leeson PD. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 2001;41:1308-15
49. Teague SJ, Davis AM, Leeson PD, Oprea TI. The design of leadlike combinatorial libraries. Angew Chem Int Ed 1999;38:3743-8
50. Makara GM. On sampling of fragment space. J Med Chem 2007;50:3214-21
51. Abad-Zapatero C. Ligand efficiency indices for effeccive drug discovery. Expert Opin Drug Discov 2007;2:469-88
52. Verheu HJ. Leadlikeness and structural diversity of synthetic screening libraries. Mol Divers 2006;10:377-88
53. Blake JF. Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. Med Chem 2005;1:649-55
54. Di L, Kerns EH. Application of pharmaceutical profiling assays for optimization of druglike properties. Curr Opin Drug Discov Develop 2005;8:495-504
55. Dance A. Microarray applications in drug discovery and development microarrays have become a critical tool in pharmaceutical research and provide in-depth analysis of the genome. Biopharm Int 2005;18:70-6
56. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today 2004;1:337-41
57. Muegge I, Enyedy IJ. Virtual screening for kinase targets. Curr Med Chem 2004;11:693-707
58. Blake JF. Examination of the computed molecular properties of compounds selected for clinical development. BioTechniques 2003;34:S16-20
59. Bleicher KH, Böhm H-J, Müller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2003;2:369-78
60. Blake JF. Integrating cheminformatic analysis in combinatorial chemistry. Curr Opin Chem Biol 2004;8:407-11
61. Hann MM, Leach AR, Green DVS. Computational chemistry, molecular complexity and screening set design. In: Oprea TI, editor, Chemoinformatics in drug discovery. Weinheim: Wiley-VCH Verlag GmbH & Co., KGaA; 2004. p. 43-57
62. Hann MM, Oprea TI. Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 2004;8:255-63
63. Leeson PD, Davis AM, Steele J. Drug-like properties: guiding principles for design - or chemical prejudice? Drug Discov Today Technol 2004;1:189-95
64. Oprea TI, Bologa C, Olah M. Compound selection for virtual screening. In: Alvarez J, Shoichet B, editors, Virtual screening in drug discovery. Boca Raton: CRC Press LLC; 2005. p. 87-106
65. Oprea TI, Allu TK, Fara DC, et al. Lead-like, drug-like or "Pub-like": how different are they? J Comput Aided Mol Des 2007;21:113-9
66. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5
67. Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem 2004;47:1303-14
68. Verlander M. Industrial applications of solid-phase peptide synthesis - a status report. Int J Pept Res Ther 2007;13:75-82
69. Labonte J, Lebbos J, Kirkpatrick P. Fresh from the pipeline: Enfuvirtide. Nat Rev Drug Discov 2003;2:345-6
70. Matthews T, Salgo M, Greenberg M, et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004;3:215-25
71. Fineman MS, Bicask TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7
72. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-5
73. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8
74. Oltersdorff T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81